Evidence map›Paper›PMID 40834859›Full record

ReviewAmerican journal of human genetics2025

Tackling a disease on a global scale, the Global Parkinson's Genetics Program, GP2: A new generation of opportunities.

Cornelis Blauwendraat, Alastair J Noyce, Ignacio F Mata, Laurel A Screven, J Solle, Sonya B Dumanis, Ekemini A Riley, Maria Teresa Periñan, Njideka Okubadejo, Christine Klein and 3 more

Abstract readReview
In one paragraph

Review in American journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Collaborative Genomics for Dystonia in Central and Eastern Europe: Successes Achieved, New Frontiers Ahead.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  3. Large-scale functional annotation establishes a reference framework for humanmedRxiv : the preprint server for health sciences · 2026
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cornelis BlauwendraatCoalition for Aligning Science, Chevy Chase, MD, USA; Global Parkinson's Genetics Program, Chevy Chase, MD, USA; Aligning Science Across Parkinson's (ASAP), Chevy Chase, MD, USA.
Alastair J NoyceCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Ignacio F MataGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Laurel A ScrevenGlobal Parkinson's Genetics Program, Chevy Chase, MD, USA.
J SolleThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Sonya B DumanisCoalition for Aligning Science, Chevy Chase, MD, USA; Aligning Science Across Parkinson's (ASAP), Chevy Chase, MD, USA.
Ekemini A RileyCoalition for Aligning Science, Chevy Chase, MD, USA; Aligning Science Across Parkinson's (ASAP), Chevy Chase, MD, USA.
Maria Teresa PeriñanCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK; Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Njideka OkubadejoDepartment of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Idi-Araba, Lagos State, Nigeria.
Christine KleinInstitute of Neurogenetics, University of Luebeck and Schleswig-Holstein University Hospital, Campus Luebeck, Luebeck, Germany.
Huw R MorrisDepartment of Clinical and Movement Neuroscience and UCL Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK.
Andrew B SingletonGlobal Parkinson's Genetics Program, Chevy Chase, MD, USA. Electronic address: andy@gp2.org.
Global Parkinson’s Genetics Program (GP2)

Funding

Additional Sequencing for the Alzheimer Disease Sequencing Project (ADSP) the Follow-Up Study (FUS), The Global Population InitiativeU01AG076482 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Clifton L Dalgard, ANTHONY JOHN GRISWOLD · 2022 to 2026
$26.9M
Modeling the impact of Women's Specific Health Factors in PD outcomes in LatinasR01NS112499 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI FERNANDEZ MATA, IGNACIO · 2020 to 2024
$3.3M
The Interplay between Genetics and Aerobic Exercise to Slow Parkinson's disease (GEARS) TrialR01NS132437 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI JAY L. ALBERTS · 2024 to 2026
$1.8M
NIA NIH HHS U01 AG076482NINDS NIH HHS R01 NS112499NINDS NIH HHS R01 NS132437
6 · The paper itself

Abstract

The need for more diversity in research is a widely recognized problem, especially in the genetics and genomics fields. While resolving this problem seems straightforward by recruiting and sequencing research participants from underrepresented populations, implementing an effort like this is complex operationally. Key considerations include ensuring equity, building capacity, and creating a sustainable research collective that works collaboratively to address local and global questions in research. Here, we provide a roadmap detailing how the Global Parkinson's Genetics Program (GP2) is tackling the lack of diversity in Parkinson disease (PD) genetics research and also reflect on 5 years of progress. GP2 aims to be a global hub facilitating subject recruitment, sample collection, data generation, harmonization, and sharing. It also acts as a centralized target discovery hub for PD genetics worldwide. The underlying tenets of GP2 center on transparency, the democratization of data and discovery, training and career support, providing (or generating) actionable results, and creating a functional collective of PD researchers worldwide. GP2 is working with 275 research groups worldwide. There are data and samples from 265,000 subjects currently committed to the program as of May 2025. We discuss the lessons learned in this process and highlight what we view as the emerging opportunities that the program will aim to target over the next period.

Indexed as

Parkinson DiseaseHumansglobal consortiumglobal geneticsParkinson diseaseprecision medicine

Identifiers

PMID40834859
PMCPMC12461011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.